Quest Diagnostics (DGX) Tops Q1 EPS by 13c, Beats on Revenue; Offers FY26 Guidance

Quest Diagnostics (NYSE: DGX) reported Q1 EPS of $2.50, $0.13 better than the analyst estimate of $2.37. Revenue for the quarter came in at $2.9 billion versus the consensus estimate of $2.83 billion.

GUIDANCE:

Quest Diagnostics sees FY2026 EPS of $10.63-$10.83, versus the consensus of $10.63. Quest Diagnostics sees FY2026 revenue of $11.78-11.9 billion, versus the consensus of $11.76 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.

You May Also Be Interested In

• Key things to know ahead of SK Hynix’s blockbuster US listing
• Arm Holdings (ARM) call put ratio 2.9 calls to 1 put, share price up 12.6%
• Applied Materials surges as CEO signals multi-year chip boom